News & Updates
Filter by Specialty:
![[MK TEST DO NOT TOUCH] Deuruxolitinib helps restore crowning glory in alopecia areata](https://sitmspst.blob.core.windows.net/images/articles/thriveaa1-and-thrive-aa2-87e6d5ec-94c6-405b-a380-d331c4dcc5fc-square.jpg)
[MK TEST DO NOT TOUCH] Deuruxolitinib helps restore crowning glory in alopecia areata
19 Aug 2024
byAudrey Abella
Pooled analyses of the phase III THRIVEAA1 and THRIVE-AA2 trials underpin the potential of the selective oral JAK* 1/2 inhibitor deuruxolitinib to effectively and safely reverse hair loss in adults with moderate-to-severe alopecia areata (AA).
[MK TEST DO NOT TOUCH] Deuruxolitinib helps restore crowning glory in alopecia areata
19 Aug 2024![[PD Test]Is exposure to antenatal corticosteroid harmful in the long run?](https://sitmspst.blob.core.windows.net/images/articles/is-exposure-to-antenatal-corticosteroid-harmful-in-the-long-run-9fd2626e-f317-43d9-b6a8-7ed550fef073-square.jpg)
[PD Test]Is exposure to antenatal corticosteroid harmful in the long run?
14 Aug 2024
byStephen Padilla
Antenatal exposure to corticosteroids, particularly betamethasone, does not increase the prevalence of cardiovascular risk factors or the incidence of major adverse cardiovascular events (MACE) up to 50 years of age, suggests a study.
